BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures,...
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...repeats and its attention to both autoimmunity and cancer. GeNeuro primarily focuses on targeting the HERVW...
...in Phase II testing for multiple sclerosis and Type I diabetes. The mAb against the HERVW...
...issued covering therapeutic modalities and diagnostic applications of repeat sequence biology Targets HERVW (ERVW-1) - Endogenous retrovirus group W member 1...
BioCentury | Mar 19, 2020
Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

...clinical research on hospitals was also a factor in GeNeuro's decision. The trial of the anti-HERVW...
...said it will provide updated guidance in its 1Q20 earnings report. Targets HERVW (ERVW-1) - Endogenous retrovirus group W member 1 Elizabeth...
BioCentury | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BioCentury | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BioCentury | Mar 12, 2019
Clinical News

GeNeuro finds path forward for temelimab in non-active progressive MS

...funding. Temelimab is a humanized IgG4 mAb targeting the envelope protein of human endogenous retrovirus group W member 1 (HERVW; ERVW-1...
...is also in a Phase IIa trial to treat Type I diabetes. Lauren Martz, Associate Editor GNbAC1 GeNeuro S.A. Endogenous retrovirus group W member 1 (HERVW) (ERVW-1) Multiple...
BioCentury | Sep 21, 2018
Company News

Servier declines rights to GeNeuro's GNbAC1

...endogenous retrovirus group W member 1 (HERVW; ERVW-1). GeNeuro S.A. (Euronext:GNRO), Geneva, Switzerland Servier, Neuilly-sur-Seine, France Business: Autoimmune Jaime De Leon GNbAC1 GeNeuro S.A. Servier Endogenous retrovirus group W member 1 (HERVW) (ERVW-1)...
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Jun 22, 2018
Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
BioCentury | Apr 20, 2018
Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
Items per page:
1 - 10 of 65